FAST NEWS: BeiGene’s Lymphoma Drug Recommended to Enter European Regulator
The latest: BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) announced Monday that its Zanubrutinib drug has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European…
RELATED ARTICLES
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG -
FAST NEWS: Beigene stock falls after Novartis terminates partnership
BGNE.US 6160.HK
-
Everest reaches new heights on growing drug sales
1952.HK
